                         SEQUENCE LISTING

<110>  Trustees of Dartmouth College
       Sentman, Charles L.
       Zhang, Tong
 
<120>  ANTI-B7-H6 ANTIBODY, FUSION PROTEINS, AND METHODS OF USING THE 
       SAME

<130>  DC0509WO

<150>  US 61/643,456
<151>  2012-05-07

<150>  US 61/705,227
<151>  2012-09-25

<160>  20    

<170>  PatentIn version 3.5

<210>  1
<211>  1418
<212>  DNA
<213>  Artificial sequence

<220>
<223>  Synthetic heavy chain sequence

<400>  1
atggaatgga cctgggtctt tctcttcctc ctgtcagtaa ctgcaggtgt ccactcccag       60

gttcagctgc agcagtctgg agctgagctg atgaagcctg gggcctcagt gaagctttcc      120

tgcaaggcta ctggctacac attcactggc tactggatag agtggataaa gcagaggcct      180

ggacatggcc ttgagtggat tggagagatt ttacctggaa ctggtagtac taactacaat      240

gagaagttca agggcaaggc cacattcact gcagatacat cctccaacac agcctacatg      300

caactcagca gcctgacaac tgaggactct gccatctatt actgtgcaat cccggggcct      360

atggactact ggggtcaagg aacctcagtc accgtctcct cagccaaaac aacagcccca      420

tcggtctatc cactggcccc tgtgtgtgga ggtacaactg gctcctcggt gactctagga      480

tgcctggtca agggttattt ccctgagcca gtgaccttga cctggaactc tggatccctg      540

tccagtggtg tgcacacctt cccagctctc ctgcagtctg gcctctacac cctcagcagc      600

tcagtgactg taacctcgaa cacctggccc agccagacca tcacctgcaa tgtggcccac      660

ccggcaagca gcaccaaagt ggacaagaaa attgagccca gagtgcccat aacacagaac      720

ccctgtcctc cactcaaaga gtgtccccca tgcgcagctc cagacctctt gggtggacca      780

tccgtcttca tcttccctcc aaagatcaag gatgtactca tgatctccct gagccccatg      840

gtcacatgtg tggtggtgga tgtgagcgag gatgacccag acgtccagat cagctggttt      900

gtgaacaacg tggaagtaca cacagctcag acacaaaccc atagagagga ttacaacagt      960

actctccggg tggtcagtgc cctccccatc cagcaccagg actggatgag tggcaaggag     1020

ttcaaatgca aggtcaacaa cagagccctc ccatccccca tcgagaaaac catctcaaaa     1080

cccagagggc cagtaagagc tccacaggta tatgtcttgc ctccaccagc agaagagatg     1140

actaagaaag agttcagtct gacctgcatg atcacaggct tcttacctgc cgaaattgct     1200

gtggactgga ccagcaatgg gcgtacagag caaaactaca agaacaccgc aacagtcctg     1260

gactctgatg gttcttactt catgtacagc aagctcagag tacaaaagag cacttgggaa     1320

agaggaagtc ttttcgcctg ctcagtggtc cacgagggtc tgcacaatca ccttacgact     1380

aagaccatct cccggactcc gggtaaatga gcggccgc                             1418


<210>  2
<211>  719
<212>  DNA
<213>  Artificial sequence

<220>
<223>  Synthetic light chain sequence

<400>  2
atggacatga ggacccctgc tcagtttctt ggaatcttgt tgctctggtt tccaggtatc       60

aaatgtgaca tcaagatgac ccagtctcca tcttccatgt atgcatctct aggagagaga      120

gtcactatca cttgcaaggc gagtcaggac attaatagct atttaagctg gttccagcag      180

aaaccaggga aatctcctaa gaccctgatc tatcgtgcaa acagattggt agatggggtc      240

ccatcaaggt tcagtggcag tggatctggg caagattatt ctctcaccat cagcagcctg      300

gagtatgaag atatgggaat ttattattgt ctacagtatg atgagtttcc gtacacgttc      360

ggagggggga ccaagctgga aataaaacgg gctgatgctg caccaactgt atccatcttc      420

ccaccatcca gtgagcagtt aacatctgga ggtgcctcag tcgtgtgctt cttgaacaac      480

ttctacccca aagacatcaa tgtcaagtgg aagattgatg gcagtgaacg acaaaatggc      540

gtcctgaaca gttggactga tcaggacagc aaagacagca cctacagcat gagcagcacc      600

ctcacgttga ccaaggacga gtatgaacga cataacagct atacctgtga ggccactcac      660

aagacatcaa cttcacccat tgtcaagagc ttcaacagga atgagtgtta ggcggccgc       719


<210>  3
<211>  121
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Synthetic heavy chain sequence

<400>  3

Gln Val Gln Leu Gln Gln Ser Gly Ala Glu Leu Met Lys Pro Gly Ala 
1               5                   10                  15      


Ser Val Lys Leu Ser Cys Lys Ala Thr Gly Tyr Thr Phe Thr Gly Tyr 
            20                  25                  30          


Trp Ile Glu Trp Ile Lys Gln Arg Pro Gly His Gly Leu Glu Trp Cys 
        35                  40                  45              


Asp Arg Ile Gly Glu Ile Leu Pro Gly Thr Gly Ser Thr Asn Tyr Asn 
    50                  55                  60                  


Glu Lys Phe Lys Gly Lys Ala Thr Phe Thr Ala Asp Thr Ser Ser Asn 
65                  70                  75                  80  


Thr Ala Tyr Met Gln Leu Ser Ser Leu Thr Thr Glu Asp Ser Ala Ile 
                85                  90                  95      


Tyr Cys Asp Arg Tyr Cys Ala Ile Pro Gly Pro Met Asp Tyr Trp Gly 
            100                 105                 110         


Gln Gly Thr Ser Val Thr Val Ser Ser 
        115                 120     


<210>  4
<211>  116
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Synthetic light chain sequence

<400>  4

Asp Ile Lys Met Thr Gln Ser Pro Ser Ser Met Tyr Ala Ser Leu Gly 
1               5                   10                  15      


Glu Arg Val Thr Ile Thr Cys Lys Ala Ser Gln Asp Ile Asn Ser Tyr 
            20                  25                  30          


Leu Ser Trp Phe Gln Gln Lys Pro Gly Lys Ser Pro Lys Thr Leu Cys 
        35                  40                  45              


Asp Arg Ile Tyr Arg Ala Asn Arg Leu Val Asp Gly Val Pro Ser Arg 
    50                  55                  60                  


Phe Ser Gly Ser Gly Ser Gly Gln Asp Tyr Ser Leu Thr Ile Ser Ser 
65                  70                  75                  80  


Leu Glu Tyr Glu Asp Met Gly Ile Tyr Tyr Cys Leu Gln Tyr Asp Glu 
                85                  90                  95      


Phe Cys Asp Arg Cys Asp Arg Pro Tyr Thr Phe Gly Gly Gly Thr Lys 
            100                 105                 110         


Leu Glu Ile Lys 
        115     


<210>  5
<211>  8
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Synthetic heavy chain variable region CDR1

<400>  5

Gly Tyr Thr Phe Thr Gly Tyr Trp 
1               5               


<210>  6
<211>  8
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Synthetic heavy chain variable region CDR2

<400>  6

Ile Leu Pro Gly Thr Gly Ser Thr 
1               5               


<210>  7
<211>  8
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Synthetic heavy chain variable region CDR3

<400>  7

Ala Ile Pro Gly Pro Met Asp Tyr 
1               5               


<210>  8
<211>  6
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Synthetic light chain variable region CDR1

<400>  8

Gln Asp Ile Asn Ser Tyr 
1               5       


<210>  9
<211>  3
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Synthetic light chain variable region CDR2

<400>  9

Arg Ala Asn 
1           


<210>  10
<211>  9
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Synthetic light chain variable region CDR3

<400>  10

Leu Gln Tyr Asp Glu Phe Pro Tyr Thr 
1               5                   


<210>  11
<211>  113
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Synthetic CD3 zeta cytoplasmic domain

<400>  11

Arg Val Lys Phe Ser Arg Ser Ala Asp Ala Pro Ala Tyr Gln Gln Gly 
1               5                   10                  15      


Gln Asn Gln Leu Tyr Asn Glu Leu Asn Leu Gly Arg Arg Glu Glu Tyr 
            20                  25                  30          


Asp Val Leu Asp Lys Arg Arg Gly Arg Asp Pro Glu Met Gly Gly Lys 
        35                  40                  45              


Pro Gln Arg Arg Lys Asn Pro Gln Glu Gly Leu Tyr Asn Glu Leu Gln 
    50                  55                  60                  


Lys Asp Lys Met Ala Glu Ala Tyr Ser Glu Ile Gly Met Lys Gly Glu 
65                  70                  75                  80  


Arg Arg Arg Gly Lys Gly His Asp Gly Leu Tyr Gln Gly Leu Ser Thr 
                85                  90                  95      


Ala Thr Lys Asp Thr Tyr Asp Ala Leu His Met Gln Ala Leu Pro Pro 
            100                 105                 110         


Arg 
    


<210>  12
<211>  86
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Synthetic CD28 hinge-transmembrane-cytoplasmic domains

<400>  12

Val Lys Gly Lys His Leu Cys Pro Ser Pro Leu Phe Pro Gly Pro Ser 
1               5                   10                  15      


Lys Pro Phe Trp Val Leu Val Val Val Gly Gly Val Leu Ala Cys Tyr 
            20                  25                  30          


Ser Leu Leu Val Thr Val Ala Phe Ile Ile Phe Trp Val Arg Ser Lys 
        35                  40                  45              


Arg Ser Arg Leu Leu His Ser Asp Tyr Met Asn Met Thr Pro Arg Arg 
    50                  55                  60                  


Pro Gly Pro Thr Arg Lys His Tyr Gln Pro Tyr Ala Pro Pro Arg Asp 
65                  70                  75                  80  


Phe Ala Ala Tyr Arg Ser 
                85      


<210>  13
<211>  327
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Synthetic CD19

<400>  13

Met Pro Pro Pro Arg Leu Leu Phe Phe Leu Leu Phe Leu Thr Pro Met 
1               5                   10                  15      


Glu Val Arg Pro Glu Glu Pro Leu Val Val Lys Val Glu Glu Gly Asp 
            20                  25                  30          


Asn Ala Val Leu Gln Cys Leu Lys Gly Thr Ser Asp Gly Pro Thr Gln 
        35                  40                  45              


Gln Leu Thr Trp Ser Arg Glu Ser Pro Leu Lys Pro Phe Leu Lys Leu 
    50                  55                  60                  


Ser Leu Gly Leu Pro Gly Leu Gly Ile His Met Arg Pro Leu Ala Ser 
65                  70                  75                  80  


Trp Leu Phe Ile Phe Asn Val Ser Gln Gln Met Gly Gly Phe Tyr Leu 
                85                  90                  95      


Cys Gln Pro Gly Pro Pro Ser Glu Lys Ala Trp Gln Pro Gly Trp Thr 
            100                 105                 110         


Val Asn Val Glu Gly Ser Gly Glu Leu Phe Arg Trp Asn Val Ser Asp 
        115                 120                 125             


Leu Gly Gly Leu Gly Cys Gly Leu Lys Asn Arg Ser Ser Glu Gly Pro 
    130                 135                 140                 


Ser Ser Pro Ser Gly Lys Leu Met Ser Pro Lys Leu Tyr Val Trp Ala 
145                 150                 155                 160 


Lys Asp Arg Pro Glu Ile Trp Glu Gly Glu Pro Pro Cys Val Pro Pro 
                165                 170                 175     


Arg Asp Ser Leu Asn Gln Ser Leu Ser Gln Asp Leu Thr Met Ala Pro 
            180                 185                 190         


Gly Ser Thr Leu Trp Leu Ser Cys Gly Val Pro Pro Asp Ser Val Ser 
        195                 200                 205             


Arg Gly Pro Leu Ser Trp Thr His Val His Pro Lys Gly Pro Lys Ser 
    210                 215                 220                 


Leu Leu Ser Leu Glu Leu Lys Asp Asp Arg Pro Ala Arg Asp Met Trp 
225                 230                 235                 240 


Val Met Glu Thr Gly Leu Leu Leu Pro Arg Ala Thr Ala Gln Asp Ala 
                245                 250                 255     


Gly Lys Tyr Tyr Cys His Arg Gly Asn Leu Thr Met Ser Phe His Leu 
            260                 265                 270         


Glu Ile Thr Ala Arg Pro Val Leu Trp His Trp Leu Leu Arg Thr Gly 
        275                 280                 285             


Gly Trp Lys Val Ser Ala Val Thr Leu Ala Tyr Leu Ile Phe Cys Leu 
    290                 295                 300                 


Cys Ser Leu Val Gly Ile Leu His Leu Gln Arg Ala Leu Val Leu Arg 
305                 310                 315                 320 


Arg Lys Arg Lys Arg Met Thr 
                325         


<210>  14
<211>  15
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Synthetic linker peptide

<400>  14

Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser 
1               5                   10                  15  


<210>  15
<211>  11
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Synthetic CD3 HCVR CDR1

<400>  15

Ser Gly Tyr Thr Phe Thr Arg Tyr Thr Met His 
1               5                   10      


<210>  16
<211>  17
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Synthetic CD3 HCVR CDR2

<400>  16

Tyr Ile Asn Pro Ser Arg Gly Tyr Thr Asn Tyr Asn Gln Lys Phe Lys 
1               5                   10                  15      


Asp 
    


<210>  17
<211>  8
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Synthetic CD3 HCVR CDR3

<400>  17

Tyr Tyr Asp Asp His Tyr Cys Leu 
1               5               


<210>  18
<211>  10
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Synthetic CD3 LCVR CDR1

<400>  18

Ser Ala Ser Ser Ser Val Ser Tyr Met Asn 
1               5                   10  


<210>  19
<211>  7
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Synthetic CD3 LCVR CDR2

<400>  19

Asp Thr Ser Lys Leu Ala Ser 
1               5           


<210>  20
<211>  8
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Synthetic CD3 LCVR CDR3

<400>  20

Gln Gln Trp Ser Ser Asn Pro Phe 
1               5               


